-
Mashup Score: 20
Both p-tau217 assays had excellent diagnostic performance for AD. Our study supports the future clinical use of commercially-available assays for p-tau217.
Source: www.thelancet.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 20
Both p-tau217 assays had excellent diagnostic performance for AD. Our study supports the future clinical use of commercially-available assays for p-tau217.
Source: www.thelancet.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2
THURSDAY, April 18, 2024 (HealthDay News) — Doctors have long known that nearly all people with Down syndrome will go on to develop Alzheimer’s disease in late
Source: www.healthday.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 219Statin Initiation and Risk of Incident Alzheimer Disease and Cognitive Decline in Genetically Susceptible Older Adults | Neurology - 21 day(s) ago
Background and ObjectivesThe association of statin initiation with incident Alzheimer disease (AD) dementia and cognitive decline by the APOE ε4 allele is unknown. Our objective was to examine whether the association of statin initiation with incident AD …
Source: www.neurology.orgCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 21Immunotherapy for Alzheimer's disease shows promise in mouse study - 1 month(s) ago
Alzheimer’s disease starts with a sticky protein called amyloid beta that builds up into plaques in the brain, setting off a chain of events that results in brain atrophy and cognitive decline. The new …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 14
Stanford researchers have uncovered a potential role for a protein called TREM1 in the development of age-related inflammation, cognitive decline, and Alzheimer’s disease. This discovery could pave the …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 24
Researchers at the University of Leeds and Lancaster University in the UK have identified a new potential target for the treatment of Alzheimer’s disease—PDE4B. Their work is published in Neuropsychopharmacology.
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 31
Nature Aging – Salvadó et al. developed and validated a CSF-based staging model for sporadic Alzheimer’s disease, which accurately reflects biomarker and clinical changes, enhancing…
Source: www.nature.comCategories: General Medicine News, NeurologyTweet-
🚨 NEW paper led by @gesalbla in @NatureAging proposes a new CSF-only staging model to characterize #Alzheimer's disease progression. PDF: https://t.co/XS8Bfy9tQE w/@_JakeVogel_ @alexa_pichetb @BrianGordon81 @SuzanneESchind1 @OskarHansson9 @biofinder_study & @WashUNeurology https://t.co/adrWXTvPd4 https://t.co/KjS6hXSgLv
-
-
Mashup Score: 11Clinical Predictors of Postmortem Amyloid and Nonamyloid Cerebral Small Vessel Disease in Middle-Aged to Older Adults | Neurology Clinical Practice - 1 month(s) ago
Background and ObjectivesSporadic cerebral small vessel disease (CSVD) is a class of important pathologic processes known to affect the aging brain and to contribute to cognitive impairment. We aimed to identify clinical risk factors associated with …
Source: www.neurology.orgCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 29
Nature Aging – Salvadó et al. developed and validated a CSF-based staging model for sporadic Alzheimer’s disease, which accurately reflects biomarker and clinical changes, enhancing…
Source: www.nature.comCategories: General Medicine News, NeurologyTweet-
🚨 NEW paper led by @gesalbla in @NatureAging proposes a new CSF-only staging model to characterize #Alzheimer's disease progression. PDF: https://t.co/XS8Bfy9tQE w/@_JakeVogel_ @alexa_pichetb @BrianGordon81 @SuzanneESchind1 @OskarHansson9 @biofinder_study & @WashUNeurology https://t.co/adrWXTvPd4 https://t.co/KjS6hXSgLv
-
Editor pick from April issue @JosephTherr @NicholasAshton @pedrorosaneto @andrealessa & coll Compared the performance of two commercially available plasma p-tau217 assays in 294 individuals with #Alzheimer's disease. Read https://t.co/FqC7XDlJTB https://t.co/3z64tKFbDB